Study identifier:D7984C00002
ClinicalTrials.gov identifier:NCT06079671
EudraCT identifier:N/A
CTIS identifier:2023-504374-38-00
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
Phase 3
No
-
Female
800
Interventional
15 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 May 2025 by AstraZeneca
AstraZeneca
Gynecologic Oncology Group Foundation, European Network for Gynaecological Oncological Trial groups
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
Location
Status
Location
Taoyuan, Taiwan, Province of China, 333
Status
Recruiting
Location
Taipei, Taiwan, Province of China, 11217
Status
Recruiting
Location
Kaohsiung, Taiwan, Province of China, 81362
Status
Recruiting
Location
Taichung, Taiwan, Province of China, 40705
Status
Recruiting
Location
Toon-Shi, Japan, 791-0295
Status
Recruiting
Location
Sapporo-shi, Japan, 003-0804
Status
Recruiting
Location
Sapporo-shi, Japan, 060-8638
Status
Withdrawn
Location
Wuhan, China, 430022
Status
Recruiting
Arms | Assigned Interventions |
---|---|
Experimental: Volrustomig Volrustomig | Biological/Vaccine: Volrustomig IV Infusion Other Name: Volrustomig |
Placebo Comparator: Placebo Placebo | Other: Placebo IV Infusion Other Name: Saline |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.